Recent advances in the understanding and management of Klebsiella pneumoniae.
David P CalfeePublished in: F1000Research (2017)
Klebsiella pneumoniae, a gram-negative bacillus of the Enterobacteriaceae family, is a component of the normal human microbiota and a common cause of community- and healthcare-associated infections. The increasing prevalence of antimicrobial resistance among K. pneumoniae isolates, particularly among those causing healthcare-associated infections, is an important public health concern. Infections caused by these multidrug-resistant organisms, for which safe and effective antimicrobial therapy options are extremely limited, are associated with poor outcomes for patients. The optimal approach to the treatment of infections caused by these multidrug-resistant strains remains undefined, and treatment decisions for an individual patient should be based on a number of organism- (for example, minimum inhibitory concentration) and patient-specific (for example, site of infection) factors. The emergence of pandrug-resistant strains of K. pneumoniae highlights the critical need for consistent implementation of effective strategies for prevention of transmission and infection and for the development of new antimicrobials with activity against these emerging pathogens.
Keyphrases
- multidrug resistant
- gram negative
- klebsiella pneumoniae
- healthcare
- drug resistant
- acinetobacter baumannii
- antimicrobial resistance
- public health
- escherichia coli
- end stage renal disease
- primary care
- newly diagnosed
- ejection fraction
- endothelial cells
- mental health
- staphylococcus aureus
- case report
- combination therapy
- stem cells
- prognostic factors
- patient reported outcomes
- pseudomonas aeruginosa
- metabolic syndrome
- social media
- peritoneal dialysis
- skeletal muscle
- replacement therapy
- adipose tissue
- respiratory tract
- health information
- patient reported
- cystic fibrosis
- glycemic control